Literature DB >> 29491151

Unique Phenotypic Characteristics of Recently Transmitted HIV-1 Subtype C Envelope Glycoprotein gp120: Use of CXCR6 Coreceptor by Transmitted Founder Viruses.

Manickam Ashokkumar1,2, Shambhu G Aralaguppe2, Srikanth P Tripathy1, Luke Elizabeth Hanna3, Ujjwal Neogi4,5.   

Abstract

Adequate information on the precise molecular and biological composition of the viral strains that establish HIV infection in the human host will provide effective means of immunization against HIV infection. In an attempt to identify the transmitted founder (TF) virus and differentiate the biological properties and infectious potential of the TF virus from those of the population of the early transmitted viruses, 250 patient-derived gp120 envelope glycoproteins were cloned in pMN-K7-Luc-IRESs-NefΔgp120 to obtain chimeric viruses. Samples were obtained from eight infants who had recently become infected with HIV through mother-to-child transmission (MTCT) and two adults who acquired infection through the heterosexual route and were in the chronic stage of infection. Among the 250 clones tested, 65 chimeric viruses were infectious, and all belonged to HIV-1 subtype C. The 65 clones were analyzed for molecular features of the envelope, per-infectious-particle infectivity, coreceptor tropism, drug sensitivity, and sensitivity to broadly neutralizing antibodies. Based on genotypic and phenotypic analysis of the viral clones, we identified 10 TF viruses from the eight infants. The TF viruses were characterized by shorter V1V2 regions, a reduced number of potential N-linked glycosylation sites, and a higher infectivity titer compared to the virus variants from the adults in the chronic stage of infection. CXCR6 coreceptor usage, in addition to that of the CCR5 coreceptor, which was used by all 65 chimeric viruses, was identified in 13 viruses. The sensitivity of the TF variants to maraviroc and a standard panel of neutralizing monoclonal antibodies (VRC01, PG09, PG16, and PGT121) was found to be much lower than that of the virus variants from the adults in the chronic stage of infection.IMPORTANCE Tremendous progress has been made during the last three and half decades of HIV research, but some significant gaps continue to exist. One of the frontier areas of HIV research which has not seen a breakthrough yet is vaccine research, which is because of the enormous genetic diversity of HIV-1 and the unique infectious fitness of the virus. Among the repertoire of viral variants, the virus that establishes successful infection (transmitted founder [TF] virus) has not been well characterized yet. An insight into the salient features of the TF virus would go a long way toward helping with the design of an effective vaccine against HIV. Here we studied the biological properties of recently transmitted viruses isolated from infants who acquired infection from the mother and have come up with unique characterizations for the TF virus that establishes infection in the human host.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  amino acid diversity; coreceptor tropism; human immunodeficiency virus; mother-to-child transmission; resistance to neutralization; transmitted founder virus

Mesh:

Substances:

Year:  2018        PMID: 29491151      PMCID: PMC5899188          DOI: 10.1128/JVI.00063-18

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

1.  Diversity of HIV type 1 long terminal repeat (LTR) sequences following mother-to-child transmission in North India.

Authors:  Ujjwal Neogi; Yogeshwar Sharma; Vikas Sood; Ajay Wanchu; Akhil C Banerjea
Journal:  AIDS Res Hum Retroviruses       Date:  2010-10-07       Impact factor: 2.205

Review 2.  The role of antibodies in HIV vaccines.

Authors:  John R Mascola; David C Montefiori
Journal:  Annu Rev Immunol       Date:  2010       Impact factor: 28.527

3.  Activity of broadly neutralizing antibodies, including PG9, PG16, and VRC01, against recently transmitted subtype B HIV-1 variants from early and late in the epidemic.

Authors:  Zelda Euler; Evelien M Bunnik; Judith A Burger; Brigitte D M Boeser-Nunnink; Marlous L Grijsen; Jan M Prins; Hanneke Schuitemaker
Journal:  J Virol       Date:  2011-05-11       Impact factor: 5.103

4.  Coreceptor usage of BOB/GPR15 and Bonzo/STRL33 by primary isolates of human immunodeficiency virus type 1.

Authors:  S P Hlmann; M Krumbiegel; F Kirchhoff
Journal:  J Gen Virol       Date:  1999-05       Impact factor: 3.891

5.  Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1.

Authors:  Xueling Wu; Zhi-Yong Yang; Yuxing Li; Carl-Magnus Hogerkorp; William R Schief; Michael S Seaman; Tongqing Zhou; Stephen D Schmidt; Lan Wu; Ling Xu; Nancy S Longo; Krisha McKee; Sijy O'Dell; Mark K Louder; Diane L Wycuff; Yu Feng; Martha Nason; Nicole Doria-Rose; Mark Connors; Peter D Kwong; Mario Roederer; Richard T Wyatt; Gary J Nabel; John R Mascola
Journal:  Science       Date:  2010-07-08       Impact factor: 47.728

6.  Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient.

Authors:  Jori Symons; Steven F L van Lelyveld; Andy I M Hoepelman; Petra M van Ham; Dorien de Jong; Annemarie M J Wensing; Monique Nijhuis
Journal:  J Antimicrob Chemother       Date:  2011-01-28       Impact factor: 5.790

7.  Functional properties of the HIV-1 subtype C envelope glycoprotein associated with mother-to-child transmission.

Authors:  Hong Zhang; Marzena Rola; John T West; Damien C Tully; Piotr Kubis; Jun He; Chipepo Kankasa; Charles Wood
Journal:  Virology       Date:  2010-01-25       Impact factor: 3.616

8.  A subcellular map of the human proteome.

Authors:  Peter J Thul; Lovisa Åkesson; Mikaela Wiking; Diana Mahdessian; Aikaterini Geladaki; Hammou Ait Blal; Tove Alm; Anna Asplund; Lars Björk; Lisa M Breckels; Anna Bäckström; Frida Danielsson; Linn Fagerberg; Jenny Fall; Laurent Gatto; Christian Gnann; Sophia Hober; Martin Hjelmare; Fredric Johansson; Sunjae Lee; Cecilia Lindskog; Jan Mulder; Claire M Mulvey; Peter Nilsson; Per Oksvold; Johan Rockberg; Rutger Schutten; Jochen M Schwenk; Åsa Sivertsson; Evelina Sjöstedt; Marie Skogs; Charlotte Stadler; Devin P Sullivan; Hanna Tegel; Casper Winsnes; Cheng Zhang; Martin Zwahlen; Adil Mardinoglu; Fredrik Pontén; Kalle von Feilitzen; Kathryn S Lilley; Mathias Uhlén; Emma Lundberg
Journal:  Science       Date:  2017-05-11       Impact factor: 47.728

9.  International technology transfer of a GCLP-compliant HIV-1 neutralizing antibody assay for human clinical trials.

Authors:  Daniel A Ozaki; Hongmei Gao; Christopher A Todd; Kelli M Greene; David C Montefiori; Marcella Sarzotti-Kelsoe
Journal:  PLoS One       Date:  2012-01-27       Impact factor: 3.240

10.  Heterosexual Transmission of Subtype C HIV-1 Selects Consensus-Like Variants without Increased Replicative Capacity or Interferon-α Resistance.

Authors:  Martin J Deymier; Zachary Ende; Angharad E Fenton-May; Dario A Dilernia; William Kilembe; Susan A Allen; Persephone Borrow; Eric Hunter
Journal:  PLoS Pathog       Date:  2015-09-17       Impact factor: 6.823

View more
  10 in total

1.  Variable infectivity and conserved engagement in cell-to-cell viral transfer by HIV-1 Env from Clade B transmitted founder clones.

Authors:  Hongru Li; Benjamin K Chen
Journal:  Virology       Date:  2018-11-08       Impact factor: 3.616

Review 2.  Deciphering DNA Methylation in HIV Infection.

Authors:  Thilona Arumugam; Upasana Ramphal; Theolan Adimulam; Romona Chinniah; Veron Ramsuran
Journal:  Front Immunol       Date:  2021-12-02       Impact factor: 7.561

3.  Specific properties of shRNA-mediated CCR5 downregulation that enhance the inhibition of HIV-1 infection in combination with shRNA targeting HIV-1 rev.

Authors:  Maria E Cardona; Jorma Hinkula; Kristin Gustafsson; Birger Christensson; Britta Wahren; Abdalla J Mohamed; C I Edvard Smith; H Jose Arteaga
Journal:  Mol Biol Rep       Date:  2022-09-12       Impact factor: 2.742

4.  Transmission and Drug Resistance Characteristics of Human Immunodeficiency Virus-1 Strain Using Medical Information Data Retrieval System.

Authors:  Ning Wang; Hui Qi; Yong Deng; Weiwei Yu; Zhong Chen
Journal:  Comput Math Methods Med       Date:  2022-06-13       Impact factor: 2.809

5.  Infection with multiple HIV-1 founder variants is associated with lower viral replicative capacity, faster CD4+ T cell decline and increased immune activation during acute infection.

Authors:  Gladys N Macharia; Ling Yue; Ecco Staller; Dario Dilernia; Daniel Wilkins; Heeyah Song; Edward McGowan; Deborah King; Pat Fast; Nesrina Imami; Matthew A Price; Eduard J Sanders; Eric Hunter; Jill Gilmour
Journal:  PLoS Pathog       Date:  2020-09-04       Impact factor: 6.823

Review 6.  HIV-1 Entry and Prospects for Protecting against Infection.

Authors:  Jean-François Bruxelle; Nino Trattnig; Marianne W Mureithi; Elise Landais; Ralph Pantophlet
Journal:  Microorganisms       Date:  2021-01-22

7.  Potent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses.

Authors:  Victor Sanchez-Merino; Eloisa Yuste; Carolina Beltran-Pavez; Ilja Bontjer; Nuria Gonzalez; Maria Pernas; Alberto Merino-Mansilla; Alex Olvera; Jose M Miro; Christian Brander; Jose Alcami; Rogier W Sanders
Journal:  J Virol       Date:  2021-10-20       Impact factor: 5.103

8.  Complement-Opsonized HIV Modulates Pathways Involved in Infection of Cervical Mucosal Tissues: A Transcriptomic and Proteomic Study.

Authors:  Cecilia Svanberg; Rada Ellegård; Elisa Crisci; Mohammad Khalid; Ninnie Borendal Wodlin; Maria Svenvik; Sofia Nyström; Kenzie Birse; Adam Burgener; Esaki M Shankar; Marie Larsson
Journal:  Front Immunol       Date:  2021-05-20       Impact factor: 7.561

Review 9.  Understanding the mechanisms driving the spread of subtype C HIV-1.

Authors:  Matthew J Gartner; Michael Roche; Melissa J Churchill; Paul R Gorry; Jacqueline K Flynn
Journal:  EBioMedicine       Date:  2020-02-27       Impact factor: 8.143

10.  An in vitro dataset on infectious potential of transmitted/founder (TF) and non-TF (NT) HIV-1 viruses generated from Interferon alpha-treated primary CD4+ T cells.

Authors:  Manickam Ashokkumar; Aanand Sonawane; Balakumaran Sathiyamani; Bennett Henzeler Esakialraj L; Luke Elizabeth Hanna
Journal:  Data Brief       Date:  2020-02-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.